ESTELLE SCHMIDT: Open Payments
NPI 1043583909 · MERRIAM, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$890 in 41 payments from 15 companies in 2025. Trend: 2023 $1,250 · 2024 $1,703 · 2025 $890
Food & beverage: $873Education: $17
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $246 |
| Regeneron Healthcare Solutions, Inc. | 3 | $99 |
| Insmed, Inc. | 5 | $97 |
| Merck Sharp & Dohme LLC | 4 | $82 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $67 |
| Lilly USA, LLC | 3 | $57 |
| Amgen Inc. | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 2 | $35 |
| Grifols USA, LLC | 1 | $33 |
| GlaxoSmithKline, LLC. | 2 | $33 |
Products named: FASENRA, DUPIXENT, TEZSPIRE, ZERBAXA, Arikayce, AIRSUPRA, OFEV, MOUNJARO.
Industry payments across KS — which companies pay providers there.
